Impact News +++ Shutterstock plummets after Getty scraps merger and editorial sale (SeekingAlpha) +++ SHUTTERSTOCK Aktie -4,01%

IBIO Aktie

>IBIO Aktienkurs

1.674 EUR +9.6% (TradegateBSX)

Ask: 1.639 EUR / 1000 Stück

Bid: 1.576 EUR / 2600 Stück

Tagesumsatz: 2438 Stück

Realtime Kurs von 7:30 bis 22 Uhr!

IBIO Aktie über LYNX handeln

Intraday

1 Jahr

>IBIO Performance

1 Woche: +1,4%

1 Monat: -5,4%

3 Monate: +3,1%

6 Monate: +4,8%

1 Jahr: -56,0%

laufendes Jahr: +4,8%

>IBIO Aktie

Name:

IBIO INC. DL -,001

Land:

USA

Sektor:

Gesundheit

ISIN/ Wkn:

US4510337086 / A3E2GR

Symbol/ Ticker:

0JV0 (Frankfurt)

Kürzel:

FRA:0JV0, ETR:0JV0, 0JV0:GR

Index:

Webseite:

https://ibioinc.com/

Profil:

iBio Inc. is a preclinical-stage biotechnology company developing next-generation biopharmaceuticals by leveraging artificial intelligence and advanced computational biology. The company focuses on creating novel antibody-based therapies for cardiome..
>Volltext..

Marktkapitalisierung:

76.17 Mio. EUR

Unternehmenswert:

12.67 Mio. EUR

Umsatz:

0.26 Mio. EUR

EBITDA:

-20.06 Mio. EUR

Nettogewinn:

-24.19 Mio. EUR

Gewinn je Aktie:

-0.51 EUR

Schulden:

2.04 Mio. EUR

Liquide Mittel:

41.73 Mio. EUR

Operativer Cashflow:

-18.93 Mio. EUR

Bargeldquote:

11.5

Umsatzwachstum:

-20%

Gewinnwachstum:

-31.51%

Dividende je Aktie:

Dividendenrendite:

Dividendenschätzung:

Insiderhandel:

Suchwörter:

IBIO

Letzte Datenerhebung:

01.07.26

>IBIO Kennzahlen

Aktien/ Unternehmen:

Aktien: 49.68 Mio. St.

Frei handelbar: 92.59%

Leerverk. Aktien: -

Rückkaufquote: -106.69%

Mitarbeiter: 20

Umsatz/Mitarb.: 0.02 Mio. EUR

Analysten:

Analystenrating: Strong buy

Kursziel: 215.71%

Bewertung:

KGV: -

KGV lG: -

KUV: 689.69

KBV: 0.78

PEG-Ratio: -

EV/EBITDA: -

Rentabilität:

Bruttomarge: -255%

Gewinnmarge: -9202%

Operative Marge: -7985.33%

Managementeffizenz:

Gesamtkaprendite: -52.61%

Eigenkaprendite: -62.09%

>IBIO Peer Group

Gesundheit, Antikörper- Behandlung, Stoffwechselerkrankungen (Diabetes/ Adipositas), Onkologie/ Krebs- Behandlung

>IBIO Chart & Kurs - Tradegate

>IBIO News

01.07.26 - 13:03	iBio Reports Single Dose of IBIO-610 Achieved Near-Complete Active Activin E Inhibition Through Eight Weeks in Obese NHP Study (GlobeNewswire EN)
	Single-dose IBIO-610 achieved up to 98% inhibition of active Activin E through eight weeks, supporting a differentiated, long-acting antibody approach...

02.06.26 - 22:06

iBio to Participate in Upcoming Healthcare Investor Conferences (GlobeNewswire EN)

SAN DIEGO, June 02, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ: IBIO) (“iBio” or the “Company”), an AI-driven innovator developing therapies for cardiometabolic, obesity and cardiopulmonary diseases, today announced that Martin Brenner, DVM, Ph.D., Chief Executive Officer and Chief Scientific Officer, and Felipe Duran, Chief Financial Officer, will participate in the Jefferies Global Healthcare Conference and the Leerink Partners Therapeutics Forum: I&I and Metabolism Conference....

02.06.26 - 13:03	iBio Becomes a Clinical-Stage Company with First Participant Dosed in Phase 1 Clinical Trial of IBIO-600 in Adults with Obesity (GlobeNewswire EN)
	IBIO-600 is potentially best-in-class, long-acting anti-myostatin monoclonal antibody designed to preserve muscle and improve body composition...

12.05.26 - 22:15	iBio GAAP EPS of -$0.07 misses by $0.01 (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

08.05.26 - 13:18	iBio Appoints Distinguished Biotech Leader, Elizabeth Stoner, to its Board of Directors (GlobeNewswire EN)
	SAN DIEGO, May 08, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ:IBIO), an AI-driven innovator developing therapies for cardiometabolic, obesity and cardiopulmonary diseases announced today the appointment of Elizabeth Stoner, M.D., M.S. to its Board of Directors....

08.04.26 - 13:03	iBio Received Regulatory Clearance to Initiate Its Phase 1 Clinical Trial of IBIO-600 in Australia (GlobeNewswire EN)
	IBIO-600 is a potentially best-in-class, long-acting anti-myostatin monoclonal antibody designed to preserve muscle and improve body compositionFirst participants expected to be dosed in 2Q 2026...

16.03.26 - 21:33	iBio to Provide an Update on Cardiopulmonary Program Targeting Pulmonary Hypertension Associated with Heart Failure with Preserved Ejection Fraction (PH-HFpEF) (GlobeNewswire EN)
	Company to host corporate update call on Tuesday, March 17, at 4 p.m. ET Company to host corporate update call on Tuesday, March 17, at 4 p.m. ET...

09.03.26 - 12:06	iBio Reports Preclinical Body Composition Data from Obese Non-Human Primates Treated with IBIO-610, a Potential First-in-Class Treatment for Fat-Selective Weight Loss (GlobeNewswire EN)
	Study demonstrated reduction of 6.7% visceral fat and 5.2% total fat mass in obese non-human primates (NHPs) despite high-calorie diet Study demonstrated reduction of 6.7% visceral fat and 5.2% total fat mass in obese non-human primates (NHPs) despite high-calorie diet...

24.02.26 - 13:03

iBio to Participate in Upcoming Investor Conferences (GlobeNewswire EN)

SAN DIEGO, Feb. 24, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ: IBIO), an AI-driven innovator of precision antibody therapies, today announced that Martin Brenner, DVM, Ph.D., Chief Executive Officer and Chief Scientific Officer, and Felipe Duran, Chief Financial Officer, will participate in fireside chats at the Oppenheimer 36th Annual Healthcare Life Sciences Conference and the Leerink Global Healthcare Conference....

10.02.26 - 22:48	iBio GAAP EPS of -$0.09 (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

10.02.26 - 22:09	iBio Reports Q2 Fiscal Year 2026 Financial Results and Provides Corporate Update (GlobeNewswire EN)
	Secured $26 Million in PIPE Financing Led by a Top-Tier Biotech Investor to Advance Preclinical Programs and Extend Cash Runway...

02.02.26 - 17:30	iBio, Inc. (IBIO) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release (Zacks)
	iBio (IBIO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations....

09.01.26 - 15:36	Privatplatzierung über 26 Mio. Dollar beflügelt Ibio-Aktie (Investing.com DE)
	Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

09.01.26 - 14:00	iBio announces private placement financing to raise ~$26M (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

09.01.26 - 13:03

iBio Announces $26 Million Private Placement (GlobeNewswire EN)

SAN DIEGO, Jan. 09, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ:IBIO), an AI-driven innovator of precision antibody therapies, today announced that it has entered into a securities purchase agreement with existing healthcare-focused, high-quality institutional investors for a private placement ("PIPE") financing that is expected to result in gross proceeds of approximately $26 million to the Company before placement agent fees and offering expenses. The offering is expected to close on or about January 13, 2026, subject to customary closing conditions....

24.11.25 - 22:18	iBio to Participate in the 8th Annual Evercore Healthcare Conference (GlobeNewswire EN)
	SAN DIEGO, Nov. 24, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ: IBIO), an AI-driven innovator of precision antibody therapies, today announced that it will participate in the 8th Annual Evercore Healthcare Conference, taking place December 2–4, 2025, in Miami....

13.11.25 - 06:24	iBio GAAP EPS of -$0.11, revenue of $0.1M beats by $0.07M (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

13.11.25 - 01:00	iBio, Inc. (IBIO) Reports Q1 Loss (Zacks)
	iBio (IBIO) delivered earnings and revenue surprises of -57.14% and 0.00%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?...

12.11.25 - 22:06	iBio Reports Q1 Fiscal Year 2026 Financial Results and Provides Corporate Update (GlobeNewswire EN)
	Strengthened cash position and extended runway into the fourth quarter of fiscal year 2027 after closing underwritten public offering with up to potentially $100 million of total gross proceeds...

23.10.25 - 13:03	iBio to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference (GlobeNewswire EN)
	SAN DIEGO, Oct. 23, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ: IBIO), an AI-driven innovator of precision antibody therapies, today announced that it will participate in the Guggenheim 2nd Annual Healthcare Innovation Conference, taking place November 10–12, 2025 in Boston....

>weitere News anzeigen...

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Gott kann nichts logisch Unmögliches tun, doch setzt dies seiner Allmacht keine Grenzen. Er kann nichts Absurdes tun oder erfinden. - Leszek Kolakowski

Partner: >TradegateBSX Börse | >Dukascopy | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram